Advances in CART Therapy for Lymphoma – Cancer Grand Rounds (UNCLCN)

Advances in CART Therapy for Lymphoma – Cancer Grand Rounds (UNCLCN)

Natalie Grover, MD

Chimeric antigen receptor T‑cell (CAR‑T) therapy has rapidly evolved from a treatment for relapsed/refractory large B‑cell lymphoma to an expanding platform with new targets, earlier‑line indications, and novel manufacturing approaches. This clinically focused Grand Rounds will review the most recent developments in CAR‑T therapy for lymphoma, including updates on efficacy, toxicity management, and emerging real-world data. The session will also highlight ongoing research in CD30-directedCAR‑T therapy and discuss its potential role across CD30‑expressing lymphomas. A patient who recently underwent CAR‑T treatment will share their journey to provide a firsthand perspective on decision-making, expectations, and survivorship.

Webinar Flyer

Hybrid Event

February 3, 2026

4:00 – 5:00 PM

In Person at

Cancer Hospital Conference Room 1 – Sanofi Aventis

101 Manning Drive

Chapel Hill, NC 27514

Or via the UNCLCN Learning Portal at https://learn.unclcn.org/cgr-11042025

This Cancer Grand Rounds is created by Lineberger Cancer Grand Rounds and supported by the UNC Lineberger Cancer Network.

Free Continuing Education Credit available:

ABIM MOC Part 2 • CME

This webinar is a part of the Cancer Grand Rounds webinar series with the UNC Lineberger Cancer Network.